THE DEVELOPMENT OF A MACROMOLECULAR DEXAMETHASONE PRODRUG FOR THE TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
$2,449,816FY2022Defense Health AgencyDOD
Board Of Regents Of The University Of Nebraska
Board Of Regents Of The University Of Nebraska